FDA Grants Priority Review for Pfizer ’s New Drug Application for Glasdegib in Patients with Previously Untreated Acute Myeloid Leukemia

June 27, 2018 - Pfizer Inc. (NYSE:PFE) today announced that the U.S. Food and Drug Administration (FDA) accepted the company ’s New Drug Application and granted Priority Review designation for glasdegib, an investigational oral smoothened (SMO)...
Source: Drugs.com - New Drug Applications - Category: Drugs & Pharmacology Source Type: news